Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jul;14(7):411-413.
doi: 10.1200/JOP.18.00311.

Promise of Immune Therapies in Multiple Myeloma

Kenneth C Anderson  1
Affiliations
Comment

Promise of Immune Therapies in Multiple Myeloma

Kenneth C Anderson. J Oncol Pract. 2018 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: Multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16:11–20. - PubMed
    1. Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252–262. - PMC - PubMed
    1. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell. 2014;25:91–101. - PMC - PubMed
    1. Xu J, Pfarr N, Endris V, et al. Molecular signaling in multiple myeloma: Association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis. 2017;6:e337. - PMC - PubMed
    1. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401–2409. - PubMed